The impact of 5-hydroxytryptamine-receptor antagonists on chemotherapy treatment adherence, treatment delay, and nausea and vomiting

Cancer Management and Research

Volumn 7, Issue , 2015, Pages 175-188

  Palli, Swetha Rao ^a   Grabner, Michael ^a   Quimbo, Ralph A ^a   Rugo, Hope S ^b  

^a HEALTHCORE INC   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adherence; CINV; Delay of therapy; Health services research; Observational; Palonosetron

Indexed keywords

CAPECITABINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; NAVELBINE; OXALIPLATIN; PACLITAXEL; PALONOSETRON; PEMETREXED; SEROTONIN ANTAGONIST; TRASTUZUMAB;

ADULT; ARTICLE; BREAST CANCER; CASE CONTROL STUDY; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; COHORT ANALYSIS; COLORECTAL CANCER; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; RETROSPECTIVE STUDY; SINGLE DRUG DOSE; THERAPY DELAY;

EID: 84936934615     PISSN: None     EISSN: 11791322     Source Type: Journal    
DOI: 10.2147/CMAR.S71355     Document Type: Article

References (36)

1. de Boer-Dennert M, de Wit R, Schmitz PI, et al. Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists. Br J Cancer. 1997;76:1055-1061.
2. Hickok JT, Roscoe JA, Morrow GR, King DK, Atkins JN, Fitch TR. Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5-hydroxytryptamine-3 antiemetics: a University of Rochester James P. Wilmot Cancer Center Community Clinical Oncology Program Study of 360 cancer patients treated in the community. Cancer. 2003;97:2880-2886.
3. Ihbe-Heffinger A, Ehlken B, Bernard R, et al. The impact of delayed chemotherapy-induced nausea and vomiting on patients, health resource utilization and costs in German cancer centers. Ann Oncol. 2004;15: 526-536.
4. Shih YC, Xu Y, Elting LS. Costs of uncontrolled chemotherapy-induced nausea and vomiting among working-age cancer patients receiving highly or moderately emetogenic chemotherapy. Cancer. 2007;110:678-685.
5. Farrell C, Brearley SG, Pilling M, Molassiotis A. The impact of chemotherapy-related nausea on patients’ nutritional status, psychological distress and quality of life. Support Care Cancer. 2013;21:59-66.
6. Roscoe JA, Morrow GR, Colagiuri B, et al. Insight in the prediction of chemotherapy-induced nausea. Support Care Cancer. 2010;18: 869-876.
7. Sun CC, Bodurka DC, Weaver CB, et al. Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer. Support Care Cancer. 2005;13: 219-227.
8. Bloechl-Daum B, Deuson RR, Mavros P, Hansen M, Herrstedt J. Delayed nausea and vomiting continue to reduce patients’ quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol. 2006;24:4472-4478.
9. Owusu C, Buist DS, Field TS, et al. Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer. J Clin Oncol. 2008;26:549-555.
10. Wilcox PM, Fetting JH, Nettesheim KM, Abeloff MD. Anticipatory vomiting in women receiving cyclophosphamide, methotrexate, and 5-FU (CMF) adjuvant chemotherapy for breast cancer. Cancer Treat Rep. 1982;66:1601-1604.
11. Roila F, Herrstedt J, Aapro M, et al. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol. 2010;21 Suppl 5:v232-v243.
12. Jordan K, Sippel C, Schmoll HJ. Guidelines for antiemetic treatment of chemotherapy-induced nausea and vomiting: past, present, and future recommendations. Oncologist. 2007;12:1143-1150.
13. Kris MG, Hesketh PJ, Somerfield MR, et al. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol. 2006;24:2932-2947.
14. ®). Breast Cancer, Version 2.2011. © 2015 National Comprehensive Cancer Network, Inc. Available at NCCN.org. Accessed: July 11, 2011.
15. ®). Colon Cancer, Version 3.2011. © 2015 National Comprehensive Cancer Network, Inc. Available at NCCN.org. Accessed: July 11, 2011.
16. ®). Rectal Cancer, Version 4.2011. © 2015 National Comprehensive Cancer Network, Inc. Available at NCCN.org. Accessed: July 11, 2011
17. ®). Small Cell Lung Cancer, Version 2.2012. © 2015 National Comprehensive Cancer Network, Inc. Available at NCCN.org. Accessed: July 11, 2011.
18. ®). Non-Small Cell Lung Cancer, Version 3.2011. © 2015 National Comprehensive Cancer Network, Inc. Available at NCCN.org. Accessed: July 11, 2011.
19. 3 RA antiemetic regimens on chemotherapy-induced nausea and vomiting associated with hospital and emergency department visits in real world practice. Support Care Cancer. 2012;20:941-949.
20. 3 RA selection within triple antiemetic regimens on uncontrolled highly emetogenic chemotherapy-induced nausea/vomiting. Expert Rev Pharmacoecon Outcomes Res. 2011;11:481-488.
21. Stoltz R, Cyong JC, Shah A, Parisi S. Pharmacokinetic and safety evaluation of palonosetron, a 5-hydroxytryptamine-3 receptor antagonist, in US and Japanese healthy subjects. J Clin Pharmacol. 2004;44:520-531.
22. 3 receptor. Anesth Analg. 2008;207: 469-478.
23. 1 receptor antagonism to prevent chemotherapy-induced nausea and vomiting. Eur J Pharmacol. 2012;684:1-7.
24. Aapro MS, Grunberg SM, Manikhas GM, et al. A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol. 2006;17:1441-1449.
25. 3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Cancer. 2003;98:473-482.
26. Gralla R, Lichinitser M, Van der Vegt S, et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol. 2003;14:1570-1577.
27. 3 receptor antagonists on chemotherapy-induced nausea and vomiting: a retrospective cohort study. BMC Health Serv Res. 2012;12:215.
28. 3 receptor antagonists for prevention of chemotherapy-induced nausea and vomiting in patients with hematologic malignancies treated with emetogenic chemotherapy in a hospital outpatient setting in the United States. J Med Econ. 2011;14:341-349.
29. ®). Antiemesis, Version 1.2012. © 2015 National Comprehensive Cancer Network, Inc. Available at NCCN.org. Accessed: August 11, 2011.
30. Sacco JJ, Botten J, Macbeth F, Bagust A, Clark P. The average body surface area of adult cancer patients in the UK: a multicentre retrospective study. PLoS One. 2010;5:e8933.
31. Hesketh PJ. Chemotherapy-induced nausea and vomiting. N Engl J Med. 2008;358:2482-2494.
32. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613-619.
33. Taylor SE, Lichtman RR, Wood JV. Compliance with chemotherapy among breast cancer patients. Health Psychol. 1984;3:553-562.
34. Silberstein S. Practice parameter: evidence-based guidelines for migraine headaches (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000;55:754-762.
35. Carlisle JB. A meta-analysis of prevention of postoperative nausea and vomiting: randomised controlled trials by Fujii et al compared with other authors. Anaesthesia. 2012;67:1076-1090.
36. Camilleri M, Parkman HP, Shafi MA, Abell TL, Gerson L. Clinical guideline: management of gastroparesis. Am J Gastroenterol. 2013;108: 18-37.